Effect of CFTR Corrector C17 on Beta-Sarcoglycanopathy
Author Information
Author(s): Martina Scano, Alberto Benetollo, Francesco Dalla Barba, Eylem Emek Akyurek, Marcello Carotti, Roberta Sacchetto, Dorianna Sandonà
Primary Institution: University of Padova
Hypothesis
Can CFTR correctors, particularly C17, be used to recover and stabilize the sarcoglycan complex in patients with beta-sarcoglycanopathy?
Conclusion
CFTR corrector C17 may serve as a potential therapeutic option for stabilizing the sarcoglycan complex in patients with beta-sarcoglycanopathy.
Supporting Evidence
- CFTR correctors preserved beta-sarcoglycan mutants from degradation.
- Corrector C17 induced a two-fold increase in beta-sarcoglycan content.
- Treatment with C17 reduced creatine kinase release from myotubes under stress.
Takeaway
This study found that a drug called C17 can help fix a problem in muscle cells from patients with a rare disease, making their muscles stronger.
Methodology
The study involved using HEK-293 cells and primary myotubes from an LGMD2E/R4 patient to assess the effects of CFTR correctors on beta-sarcoglycan mutants.
Limitations
The primary cells from the patient had a low differentiative capacity, which may affect the results.
Participant Demographics
The study involved primary myotubes derived from an LGMD2E/R4 patient.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website